A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

Phase 1TerminatedNCT03804515

Spectrum Pharmaceuticals, Inc2 enrolled

Overview

The purpose of this study is to determine routes of excretion and single-dose PK parameters for poziotinib in patients with solid tumors with EGFR or HER2 mutations or EGFR/HER2 overexpression/amplification.

This is a Phase 1, open-label, single-dose study of 14C-labeled poziotinib to determine routes of excretion and single-dose PK parameters for poziotinib in patients with solid tumors with EGFR or HER2 mutations or EGFR/HER2 overexpression/amplification. On Day 1, enrolled patients will be admitted to the inpatient unit and all predose assessments will be completed. Patients will be admitted to the inpatient unit for 9 days. On Day 2, a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally in the morning right after breakfast with at least 200 mL of water. Over the following 168 hours, urine and feces will be collected and pooled at specified intervals for measurement of total radioactivity recovered and subsequent determination of the routes of elimination of poziotinib and its metabolites. Blood samples will be taken at specified time points for 168 hours after dosing for estimation of single-dose poziotinib PK parameters.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Solid Tumor

Interventions

14C-labeled poziotinibDRUG

a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient can be male or female and is at least 18 years of age * Patient must be willing and capable of giving written Informed Consent and willing to stay in the research unit for 9 days. * Patient has a life expectancy of at least 6 months. * Histological confirmation of solid tumor cancer that is suitable for poziotinib therapy. These may include patients with any solid malignancy with either EGFR or HER 2 mutations or EGFR/HER2 overexpression/amplification. Brain metastases are allowed, if patient is clinically stable and does not require treatment with anticonvulsants or escalating steroid doses. Exclusion Criteria: * Patient has a diagnosis of primary and or metastatic hepatic or renal carcinomas. * Patient is unable to take oral medication or has ongoing Grade ≥2 diarrhea due to any etiology including Crohn's disease and/or ulcerative colitis. * Previous poziotinib exposure * Patient has previously participated in a study utilizing 14C. * Patient has any pathology or history of procedures expected to change absorption * Patient has a PEG (Percutaneous Endoscopic Gastrostomy) tube

Locations (1)

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Outcomes

Primary Outcomes

Maximum recovery of the radioactive dose in plasma, urine and feces

The route of excretion of radioactive poziotinib and its metabolites following single oral administration of 14C-labeled poziotinib in patients with solid tumors suitable for treatment with poziotinib.

Time frame: 1 year

Secondary Outcomes

The concentration of 14C-labeled poziotinib and its metabolites in plasma, urine and feces

To identify major metabolites of poziotinib

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.